These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26165763)

  • 1. Rethinking tamoxifen in the management of melanoma: New answers for an old question.
    Ribeiro MPC; Santos AE; Custódio JBA
    Eur J Pharmacol; 2015 Oct; 764():372-378. PubMed ID: 26165763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.
    Yang G; Nowsheen S; Aziz K; Georgakilas AG
    Pharmacol Ther; 2013 Sep; 139(3):392-404. PubMed ID: 23711794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
    Jordan VC
    Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PharmGKB summary: tamoxifen pathway, pharmacokinetics.
    Klein DJ; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE
    Pharmacogenet Genomics; 2013 Nov; 23(11):643-7. PubMed ID: 23962908
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenetics of anti-estrogen treatment of breast cancer.
    Del Re M; Michelucci A; Simi P; Danesi R
    Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular aspects of different mechanisms of tamoxifen resistance].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
    Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
    Jayaraman S; Reid JM; Hawse JR; Goetz MP
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
    Ahmed NS; Elghazawy NH; ElHady AK; Engel M; Hartmann RW; Abadi AH
    Eur J Med Chem; 2016 Apr; 112():171-179. PubMed ID: 26896706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tamoxifen dilemma.
    White IN
    Carcinogenesis; 1999 Jul; 20(7):1153-60. PubMed ID: 10383884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
    Higgins MJ; Stearns V
    Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.